After the deal closes, Biogen will be in charge of developing and selling Alcyone's ThecaFlex DRx implantable subcutaneous port and catheter device.

The firm is focusing its resources on pipeline assets like IPH4502, an antibody-drug conjugate under development for treating Nectin-4-expressing cancers.

Signals from a Phase Ia trial of LP-184 in solid tumors suggested that patients with DNA damage response gene mutations might respond well to the drug.

The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing ...

The trial will initially test the drug in patients with advanced or metastatic solid tumors and then in patients with biomarker-defined cancers.

In two Phase I expansion cohorts, the firm is studying KTX-1001 with BMS's mezigdomide or Onyx's carfilzomib in patients with t(4;14) translocations.

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

Kwangdong will pay Ocugen up to $7.5 million for rights to sell OCU400 in South Korea, plus further milestone payments and royalties on net sales.

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Vyjuvek was approved in 2023, initially for patients at least six months of age, and could only be applied by healthcare professionals.

The agency said it will accept data from single-arm trials in its newly released Rare Disease Evidence Principles, but ...